Kenvue Inc (KVUE)
21.77
+0.16
(+0.74%)
USD |
NYSE |
Dec 20, 16:00
21.83
+0.06
(+0.28%)
Pre-Market: 06:27
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 41.74B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 8.01% |
| Valuation | |
| PE Ratio | 39.58 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.705 |
| Price to Book Value | 3.921 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.205 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.8175 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Kenvue is the world’s largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power. |
| URL | https://www.kenvue.com |
| Investor Relations URL | https://investors.kenvue.com/overview/default.aspx |
| HQ State/Province | New Jersey |
| Sector | Consumer Staples |
| Industry | Personal Care Products |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Feb. 07, 2025 (est.) |
| Last Earnings Release | Nov. 07, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 13, 2024 |
Ratings
Profile
| Kenvue is the world’s largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power. |
| URL | https://www.kenvue.com |
| Investor Relations URL | https://investors.kenvue.com/overview/default.aspx |
| HQ State/Province | New Jersey |
| Sector | Consumer Staples |
| Industry | Personal Care Products |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Feb. 07, 2025 (est.) |
| Last Earnings Release | Nov. 07, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 13, 2024 |